CL2017001718A1 - Derivados de glucagón con estabilidad mejorada - Google Patents
Derivados de glucagón con estabilidad mejoradaInfo
- Publication number
- CL2017001718A1 CL2017001718A1 CL2017001718A CL2017001718A CL2017001718A1 CL 2017001718 A1 CL2017001718 A1 CL 2017001718A1 CL 2017001718 A CL2017001718 A CL 2017001718A CL 2017001718 A CL2017001718 A CL 2017001718A CL 2017001718 A1 CL2017001718 A1 CL 2017001718A1
- Authority
- CL
- Chile
- Prior art keywords
- glucagon
- improved stability
- hypoglucemia
- prevention
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A UN NUEVO PÉPTIDO DERIVADO DEL GLUCAGÓN Y A UNA COMPOSICIÓN PARA LA PREVENCIÓN O EL TRATAMIENTO DE HIPOGLUCEMIA, QUE CONTIENE EL NUEVO PÉPTIDO DERIVADO DEL GLUCAGÓN COMO PRINCIPIO ACTIVO. EL DERIVADO DE GLUCAGÓN DE ACUERDO CON LA PRESENTE INVENCIÓN TIENE PROPIEDADES FÍSICAS MEJORADAS DEBIDO AL CAMBIO EN EL PUNTO ISOELÉCTRICO (PI) MIENTRAS QUE ES CAPAZ DE MANTENER UNA ACTIVIDAD EN LOS RECEPTORES DEL GLUCAGÓN Y, POR TANTO, PUEDE MEJORAR LA CONFORMIDAD DEL PACIENTE CUANDO SE USA COMO UN AGENTE HIPOGLUCÉMICO Y TAMBIÉN ES ADECUADO PARA LA ADMINISTRACIÓN EN COMBINACIÓN CON OTROS AGENTES ANTIOBESIDAD. POR CONSIGUIENTE, EL DERIVADO DE GLUCAGÓN DE ACUERDO CON LA PRESENTE INVENCIÓN SE PUEDE USAR DE MANERA EFICAZ PARA LA PREVENCIÓN Y EL TRATAMIENTO DE LA HIPOGLUCEMIA Y LA OBESIDAD.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140193800 | 2014-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001718A1 true CL2017001718A1 (es) | 2018-01-12 |
Family
ID=56284642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001718A CL2017001718A1 (es) | 2014-12-30 | 2017-06-28 | Derivados de glucagón con estabilidad mejorada |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11135271B2 (es) |
| EP (2) | EP3241841A4 (es) |
| JP (2) | JP6797122B2 (es) |
| KR (1) | KR102291020B1 (es) |
| CN (1) | CN107636009B (es) |
| AR (1) | AR103322A1 (es) |
| AU (1) | AU2015372818A1 (es) |
| CA (1) | CA2972748A1 (es) |
| CL (1) | CL2017001718A1 (es) |
| CO (1) | CO2017006308A2 (es) |
| CR (1) | CR20170293A (es) |
| DO (1) | DOP2017000156A (es) |
| EA (1) | EA035527B1 (es) |
| EC (1) | ECSP17040923A (es) |
| GT (1) | GT201700150A (es) |
| HK (1) | HK1248713A1 (es) |
| IL (2) | IL253206B (es) |
| MA (1) | MA40709B1 (es) |
| MX (1) | MX2017008569A (es) |
| MY (1) | MY185334A (es) |
| NZ (1) | NZ733464A (es) |
| PE (2) | PE20230304A1 (es) |
| PH (1) | PH12017501222A1 (es) |
| SG (1) | SG11201705376SA (es) |
| TN (1) | TN2017000271A1 (es) |
| TW (1) | TW201639878A (es) |
| UA (1) | UA126960C2 (es) |
| WO (1) | WO2016108586A1 (es) |
| ZA (1) | ZA201705015B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015372818A1 (en) | 2014-12-30 | 2017-07-27 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| TN2017000555A1 (en) * | 2015-06-30 | 2019-04-12 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| DK3398961T3 (da) | 2015-12-31 | 2022-08-22 | Hanmi Pharm Ind Co Ltd | Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor |
| AU2017289014B2 (en) * | 2016-06-29 | 2019-12-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| MX2019009149A (es) | 2017-02-03 | 2019-10-14 | Hanmi Pharm Ind Co Ltd | Conjugado de material bioactivo que tiene sustentabilidad mejorada y uso del mismo. |
| EP3708661A4 (en) * | 2017-12-22 | 2021-12-01 | Hanmi Pharm. Co., Ltd. | NEW STRUCTURED THERAPEUTIC ENZYME FUSION PROTEIN AND ITS USE |
| US20210030847A1 (en) * | 2018-01-23 | 2021-02-04 | Xeris Pharmaceuticals, Inc. | Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon |
| KR20200078414A (ko) | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 인슐린 및 글루카곤을 포함하는 약학 조성물 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| AU2021277116A1 (en) | 2020-05-22 | 2023-02-02 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long-acting conjugate of glucagon derivative |
| US20230310631A1 (en) | 2020-07-15 | 2023-10-05 | Hanmi Pharm. Co., Ltd. | Therapeutic use of glucagon derivative or conjugate thereof for liver disease |
| EP4321170A1 (en) | 2021-04-09 | 2024-02-14 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating chronic kidney disease containing glucagon derivative |
| KR20230095666A (ko) * | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN115490760B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| PT1605897E (pt) | 2003-03-19 | 2012-09-10 | Lilly Co Eli | Compostos de glp-1 ligado a polietilenoglicol |
| EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| EP2007804B1 (en) | 2006-04-20 | 2014-06-18 | Amgen, Inc | Glp-1 compounds |
| ES2628063T3 (es) * | 2007-01-05 | 2017-08-01 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| JP5646848B2 (ja) | 2007-06-19 | 2014-12-24 | 株式会社糖鎖工学研究所 | 糖鎖付加ｇｌｐ−１ペプチド |
| US8895694B2 (en) | 2007-09-05 | 2014-11-25 | Novo Nordisk A/S | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| JP5887265B2 (ja) | 2009-06-16 | 2016-03-16 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | Ｇｉｐ受容体活性グルカゴン化合物 |
| SI2454282T1 (sl) | 2009-07-13 | 2015-06-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| EP2512503A4 (en) * | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| EP2525809B1 (en) * | 2010-01-20 | 2016-08-03 | Zealand Pharma A/S | Glucagon-glp1 dual agonists for use in the treatment of cardiac conditions |
| RU2559320C2 (ru) | 2010-03-26 | 2015-08-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| BR112013015389A2 (pt) * | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| JP6284471B2 (ja) | 2011-05-18 | 2018-02-28 | メデリス ダイアビーティーズ，エルエルシー | インスリン抵抗性のための改善されたペプチドの調合薬 |
| DK3878859T3 (da) * | 2011-06-10 | 2024-01-02 | Hanmi Science Co Ltd | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse |
| HUE042585T2 (hu) | 2011-06-17 | 2019-07-29 | Hanmi Science Co Ltd | Oxintomodulint és immunglobulin-fragmentumot tartalmazó konjugátum és alkalmazása |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| RU2014117678A (ru) * | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
| RS57347B1 (sr) | 2012-06-21 | 2018-08-31 | Univ Indiana Res & Tech Corp | Analozi glukagona koji ispoljavaju aktivnost gip receptora |
| US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EP2916819B1 (en) | 2012-11-06 | 2019-07-10 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| CA2891929C (en) | 2012-11-20 | 2022-07-19 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| PL2934567T3 (pl) | 2012-12-21 | 2018-10-31 | Sanofi | Pochodne eksendyny-4 jako podwójny agonista GLP1/GIP lub potrójny agonista GLP1/GIP/glukagon |
| MY174727A (en) * | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| EP3206710B1 (en) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Incretin-insulin conjugates |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| AU2015372818A1 (en) | 2014-12-30 | 2017-07-27 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
| TN2017000555A1 (en) | 2015-06-30 | 2019-04-12 | Hanmi Pharm Ind Co Ltd | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| DK3398961T3 (da) | 2015-12-31 | 2022-08-22 | Hanmi Pharm Ind Co Ltd | Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor |
-
2015
- 2015-12-30 AU AU2015372818A patent/AU2015372818A1/en not_active Abandoned
- 2015-12-30 JP JP2017535417A patent/JP6797122B2/ja active Active
- 2015-12-30 TN TN2017000271A patent/TN2017000271A1/en unknown
- 2015-12-30 MX MX2017008569A patent/MX2017008569A/es unknown
- 2015-12-30 US US15/540,729 patent/US11135271B2/en active Active
- 2015-12-30 KR KR1020150189532A patent/KR102291020B1/ko active IP Right Grant
- 2015-12-30 UA UAA201707040A patent/UA126960C2/uk unknown
- 2015-12-30 EA EA201791333A patent/EA035527B1/ru not_active IP Right Cessation
- 2015-12-30 WO PCT/KR2015/014422 patent/WO2016108586A1/ko active Application Filing
- 2015-12-30 CN CN201580077186.3A patent/CN107636009B/zh active Active
- 2015-12-30 MY MYPI2017000967A patent/MY185334A/en unknown
- 2015-12-30 NZ NZ733464A patent/NZ733464A/en unknown
- 2015-12-30 EP EP15875680.9A patent/EP3241841A4/en not_active Withdrawn
- 2015-12-30 EP EP19172184.4A patent/EP3575314B1/en active Active
- 2015-12-30 TW TW104144427A patent/TW201639878A/zh unknown
- 2015-12-30 PE PE2022001996A patent/PE20230304A1/es unknown
- 2015-12-30 MA MA40709A patent/MA40709B1/fr unknown
- 2015-12-30 CA CA2972748A patent/CA2972748A1/en active Pending
- 2015-12-30 SG SG11201705376SA patent/SG11201705376SA/en unknown
- 2015-12-30 CR CR20170293A patent/CR20170293A/es unknown
- 2015-12-30 PE PE2017001168A patent/PE20171154A1/es unknown
- 2015-12-30 AR ARP150104340A patent/AR103322A1/es unknown
-
2017
- 2017-06-27 CO CONC2017/0006308A patent/CO2017006308A2/es unknown
- 2017-06-27 IL IL253206A patent/IL253206B/en unknown
- 2017-06-28 CL CL2017001718A patent/CL2017001718A1/es unknown
- 2017-06-28 GT GT201700150A patent/GT201700150A/es unknown
- 2017-06-28 EC ECIEPI201740923A patent/ECSP17040923A/es unknown
- 2017-06-29 PH PH12017501222A patent/PH12017501222A1/en unknown
- 2017-06-29 DO DO2017000156A patent/DOP2017000156A/es unknown
- 2017-07-24 ZA ZA2017/05015A patent/ZA201705015B/en unknown
-
2018
- 2018-04-10 HK HK18104685.2A patent/HK1248713A1/zh unknown
-
2020
- 2020-08-28 JP JP2020144259A patent/JP7079301B2/ja active Active
-
2021
- 2021-03-09 IL IL281375A patent/IL281375B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001718A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2018000684A1 (es) | Moduladores de la proteína de núcleo de la hepatitis b. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| CL2016000952A1 (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2018000978A1 (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| CL2017001438A1 (es) | Antagonistas de miostatina o activina para el tratamiento de sarcopenia | |
| UY36342A (es) | Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos | |
| CR20160367A (es) | Compuesto heterocíclico fusionado | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| TW201613633A (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
| CL2015002698A1 (es) | Nuevos compuestos y composiciones para la inhibicion de fasn | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| CL2017001904A1 (es) | Composición para el tratamiento de enfermedad veno-oclusiva hepática. | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| DOP2017000146A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| EA201891783A1 (ru) | Композиция для растворения аморфных дитиазинов и способ ее применения |